<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72185">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903642</url>
  </required_header>
  <id_info>
    <org_study_id>Bonnotte PHRC IR 2008</org_study_id>
    <nct_id>NCT01903642</nct_id>
  </id_info>
  <brief_title>Study of the Proteome and Cytokines During Inflammatory Syndromes of Different Etiologies.</brief_title>
  <acronym>Proteome</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypotheses of our research are based on the fact that various pathological states,
      infection, cancer, inflammatory disease, can induce an inflammatory syndrome, through
      different pathways, even though the clinical presentation can be identical. The
      identification of biological markers specific to an etiology would therefore allow a faster
      diagnosis and improve care for patients. We thus took an interest in the three groups of
      diseases most frequently responsible for an inflammatory syndrome, infections, cancers and
      auto-immune diseases. To achieve this, various methods will be used.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>determination of usual parameters of inflammation</measure>
    <time_frame>at baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Inflammatory Disease</condition>
  <arm_group>
    <arm_group_label>Patients with inflammatory syndrome</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>proteomic analysis</intervention_name>
    <arm_group_label>Patients with inflammatory syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients presenting an inflammatory syndrome, defined by elevated C-reactive protein
        (CRP&gt;50mg/L), whose etiology is related to infection, cancer or an inflammatory disease.

          -  Patients not on treatment (corticoids, immunosuppressive drugs) during the 7 days
             preceding inclusion

          -  Age: 18-90 years

          -  Patients covered by the National Health Insurance Agency

          -  signed written informed consent form

        Exclusion Criteria:

          -  - Any patient not meeting the inclusion criteria

          -  Pregnant patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 17, 2013</lastchanged_date>
  <firstreceived_date>July 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
